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Coagulation factor levels in solvent/detergent-
treated plasma
Recently, an extensive committee report on the current sta-
tus of solvent/detergent (S/D)-treated frozen plasma was
published by Klein et al.1 in TRANSFUSION. Although S/D-
treated plasma is now widely used, little is published about
the amount and the stability of the individual coagulation
factors in S/D-treated plasma.2,3 According to the manufac-
turers, S/D treatment does not significantly alter the con-
centration of coagulation factors, and a concentration of the
individual coagulation factors of at least >0.50 U per mL
(50% of normal) is guaranteed. Although this level is above
the hemostatic value of most coagulation factors, it may be
insufficient for correction of severe deficiencies of coagu-
lation factors.
We studied the levels of several coagulation factors in
seven batches of S/D-treated plasma (ESDEP, CLB,
Amsterdam, the Netherlands). This S/D-treated plasma is
prepared from pooled fresh-frozen plasma (FFP) from
healthy unpaid Dutch blood donors. The technology used
to prepare S/D-treated plasma was developed by
Octopharma AG (Glarus, Switzerland).4 S/D-treated plasma
was thawed in a waterbath at 37oC for 20 minutes accord-
ing to the manufacturer’s instructions. Plasma samples
were tested in duplicate immediately after thawing and
after storage at room temperature for 2, 4, and 8 hours.
Antithrombin, plasminogen, and antiplasmin were mea-
sured wtih chromogenic assays. Other coagulation factors,
including protein S and protein C activity; factors II, V, VII,
VIII, IX, X, XI, and XII; and fibrinogen, were determined ac-
cording to standard clotting assay
procedures. Protein C, protein S, and
von Willebrand factor (vWF) antigen
levels, as well as binding of vWF to
collagen were determined by en-
zyme-linked immunosorbent assays.
For our laboratory assays, reference
pooled plasma was obtained from 40
healthy volunteers. Coagulation fac-
tors were not determined in FFP be-
fore S/D treatment.
The results of the concentrations
and activities of coagulation factors in
S/D-treated plasma are shown in Table
1. Most coagulation factors are present
at a level that is found in normal
pooled plasma. However, antiplasmin
and protein S activities are decreased
to less than 50 percent of those in nor-
mal pooled plasma. All coagulation
factors were stable at room tempera-
ture for at least 8 hours, except pro-
tein S activity, which decreased from a median of 0.45 U per
mL (range, 0.42-0.53) to one of 0.34 U per mL (0.29-0.36).
The low levels of antiplasmin and protein S activity in
S/D-treated plasma may be of clinical importance. Besides
being low in patients with a congenital antiplasmin defi-
ciency, the levels of antiplasmin can be greatly decreased
in patients with severe liver disease, after thrombolytic
therapy, during liver transplantation, in patients with amy-
loidosis, and in patients with acute promyelocytic leuke-
mia.5,6 In these patients, the infusion of S/D-treated plasma
may be insufficient to correct the antiplasmin deficiency.
It is known that levels of 50 percent, as are found in patients
who are heterozygous for antiplasmin deficiency, may be
associated with a mild hemorrhagic tendency.5 Therefore,
in case of severe antiplasmin deficiency, FFP instead of S/
D-treated plasma may be required to achieve an
antiplasmin level >50 percent of normal.
The importance of the low levels of protein S is less
clear. Hereditary protein S deficiency is associated with a
thrombotic tendency. In patients with purpura fulminans
caused by bacterial or viral infections, reduced levels of
protein C and protein S have been reported.7 Because these
patients are nearly always treated with plasma substitution,
the concentration of proteins S and C in the infused plasma
may be of importance. Theoretically, the infusion of plasma
that is deficient in protein S may be less effective in this
patient group than the infusion of FFP.
All other coagulation factors that we measured, includ-
ing vWF, were present at normal levels when compared to
the levels in normal pooled plasma. Earlier studies indi-
TABLE 1. Coagulation factor levels in S/D-treated plasma
Factor* Median Range Normal range
Antithrombin 0.84 0.81 - 0.89 0.80 - 1.20
Fibrinogen 2.6 2.6 - 2.7 1.5 - 3.6
Antiplasmin 0.47 0.45 - 0.49 0.80 - 1.20
Factor
II 0.85 0.72 - 0.88 0.60 - 1.40
V 0.87 0.81 - 0.90 0.50 - 1.50
VII 1.00 0.95 - 1.04 0.60 - 1.40
VIII 0.92 0.78 - 1.01 0.60 - 1.40
IX 0.83 0.80 - 0.99 0.60 - 1.40
X 0.84 0.79 - 0.85 0.60 - 1.40
XI 0.95 0.88 - 1.00 0.60 - 1.40
XII 0.93 0.85 - 1.03 0.60 - 1.40
VWF
Antigen 1.65 1.60 - 1.95 0.60 - 1.40
Collagen-binding activity 1.05 0.86 - 1.26 0.60 - 1.40
Plasminogen 0.93 0.87 - 1.01 0.85 - 1.20
Protein S
Total 0.85 0.79 - 0.93 0.70 - 1.40
Activity 0.45 0.42 - 0.53 0.70 - 1.40
Free 0.83 0.72 - 0.95 0.76 - 1.40
Protein C
Antigen 1.05 0.95 - 1.18 0.70 - 1.40
Activity 0.69 0.66 - 0.71 0.70 - 1.40
* All values U per mL, except for fibrinogen, for which values are g per L.
LETTERS TO THE EDITOR
Volume 39, October 1999   TRANSFUSION   1151
cated, however, that the levels of high-molecular-weight
vWF multimers are lower in S/D-treated plasma than in FFP.
The clinical importance of this decrease is not yet known.8,9
In conclusion, we state that virus-inactivated plasma
obtained by S/D treatment contains normal levels of nearly
all coagulation factors and that, in our system, those factors
are stable even after the plasma has rested for 8 hours at
room temperature. However, it is important to be aware that
S/D-treated plasma has low levels of antiplasmin and pro-
tein S. Therefore, in cases in which severe coagulation dis-
turbances are corrected by S/D-treated plasma infusion, it
would be advisable to measure these individual coagulation
factors. Clinical studies are necessary to establish the clini-
cal importance of these low coagulation factor levels in
S/D-treated plasma.
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